NCT04575935 2026-03-05
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06990503 2025-05-25
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT03353831 2025-04-06
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
AGO Research GmbH
Phase 3 Completed
NCT03632798 2025-02-12
ACSCO
Cordgenics, LLC
Phase 3 Withdrawn
NCT03949283 2024-08-22
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Cordgenics, LLC
Phase 3 Active not recruiting
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT03642132 2023-04-06
JAVELIN OVARIAN PARP100
Pfizer
Phase 3 Terminated
NCT01684878 2017-05-23
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
Hoffmann-La Roche
Phase 3 Completed
NCT00002895 2013-12-04
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003695 2013-12-04
Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer
National Cancer Institute (NCI)
Phase 3 Completed